Table 4 Body condition, obesity, additional diseases, and corticosteroid treatment
From: Prevalence and risk factors for laminitis within the Norwegian pony breed Nordlandshest/Lyngshest
Body score, regional adiposity, diseases, and corticosteroid treatment | n (%) | Prevalence of laminitis (2017–2019), n (%) |
|---|---|---|
Body condition score (BCS) | ||
0 | 0 (0) | 0 (0) |
1 | 0 (0) | 0 (0) |
2 | 9 (2.0) | 0 (0) |
3 | 265 (58.4) | 16 (6.0) |
4 | 172 (37.9) | 18 (10.5) |
5 | 8 (1.8) | 5 (62.5) |
Missing | 10 | |
Regional adiposity | ||
Yes | 105 (22.6) | 18 (17.1) |
No | 359 (77.4) | 21 (5.9) |
Additional diseases in 2017–2019 | ||
Yes | 148 (31.9) | 28 (18.9) |
No | 316 (68.1) | 11 (3.5) |
Additional diseases* | ||
Allergic dermatitis (eczema) | 8 | 3 (37.5) |
Colic | 59 | 6 (10.2) |
Enteritis | 8 | 0 (0) |
Equine metabolic syndrome | 3 | 2 (66.7) |
Gastric ulcer | 2 | 0 (0) |
Lameness | 44 | 13 (29.6) |
Metritis | 2 | 1 (50.0) |
Other disease | 53 | 15 (28.3) |
Pituitary pars intermedia dysfunction | 3 | 1 (33.3) |
Pneumonia | 7 | 0 (0) |
Respiratory disease | 2 | 0 (0) |
No additional disease | 316 | 11 (3.5) |
Corticosteroid treatment for lameness | ||
Intraarticular | 7 | 1 (14.3) |
Intravenous | 1 | 0 (0) |
Oral (prednisolone) | 3 | 3 (100) |
No treatment | 34 | 9 (26.5) |
Corticosteroids for eczema | ||
Yes | 3 | 2 (66.7) |
No | 5 | 1 (20) |